14 years of historical data (2013–2026) · Healthcare · Medical - Healthcare Information Services
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
HealthEquity, Inc. trades at 34.6x earnings, 59% below its 5-year average of 84.7x, sitting at the 0th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.1x, the stock trades at a premium of 57%. On a free-cash-flow basis, the stock trades at 15.7x P/FCF, 94% below the 5-year average of 275.4x.
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $7.1B | $7.5B | $9.8B | $6.6B | $5.1B | $4.4B | $6.3B | $4.5B | $4.0B | $3.1B | $2.8B |
| Enterprise Value | $7.8B | $8.2B | $10.6B | $7.1B | $5.9B | $5.2B | $7.1B | $5.6B | $3.6B | $2.9B | $2.6B |
| P/E Ratio → | 34.64 | 34.83 | 101.30 | 118.09 | — | — | 696.25 | 113.90 | 53.28 | 65.74 | 105.11 |
| P/S Ratio | 5.42 | 5.71 | 8.18 | 6.57 | 5.96 | 5.87 | 8.62 | 8.50 | 13.75 | 13.64 | 15.53 |
| P/B Ratio | 3.54 | 3.56 | 4.64 | 3.23 | 2.71 | 2.40 | 4.59 | 4.39 | 8.28 | 9.04 | 10.58 |
| P/FCF | 15.65 | 16.47 | 29.04 | 33.40 | 163.00 | 1135.06 | 74.69 | 70.90 | 40.16 | 64.80 | 84.16 |
| P/OCF | 15.58 | 16.39 | 28.86 | 27.07 | 34.11 | 31.51 | 34.81 | 42.72 | 34.83 | 38.32 | 60.76 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
HealthEquity, Inc.'s enterprise value stands at 24.2x EBITDA, 11% below its 5-year average of 27.3x. The Healthcare sector median is 14.2x, placing the stock at a 70% premium on an enterprise-value basis.
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 6.23 | 8.85 | 7.10 | 6.82 | 6.91 | 9.64 | 10.59 | 12.49 | 12.77 | 14.75 |
| EV / EBITDA | 24.21 | 25.36 | 27.06 | 25.25 | 29.56 | 29.40 | 36.08 | 34.24 | 37.44 | 41.66 | 48.35 |
| EV / EBIT | 24.21 | 25.36 | 60.66 | 54.91 | 569.18 | — | 181.16 | 82.90 | 47.17 | 55.88 | 65.56 |
| EV / FCF | — | 17.97 | 31.44 | 36.09 | 186.48 | 1335.06 | 83.51 | 88.29 | 36.48 | 60.67 | 79.90 |
Margins and return-on-capital ratios measuring operating efficiency
HealthEquity, Inc. earns an operating margin of 24.6%. Operating margins have expanded from 12.8% to 24.6% over the past 3 years, signaling improving operational efficiency. ROE of 10.2% is modest. ROIC of 8.5% represents adequate returns on invested capital.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 69.5% | 69.5% | 57.7% | 53.0% | 45.9% | 45.1% | 46.2% | 54.7% | 61.0% | 56.7% | 57.2% |
| Operating Margin | 24.6% | 24.6% | 19.2% | 12.8% | 4.4% | 5.4% | 10.9% | 20.5% | 27.0% | 23.7% | 23.1% |
| Net Profit Margin | 16.4% | 16.4% | 8.1% | 5.6% | -3.0% | -5.9% | 1.2% | 7.5% | 25.7% | 20.6% | 14.8% |
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 10.2% | 10.2% | 4.7% | 2.8% | -1.4% | -2.7% | 0.7% | 5.3% | 18.0% | 15.6% | 11.3% |
| ROA | 6.3% | 6.3% | 2.9% | 1.8% | -0.8% | -1.5% | 0.3% | 2.6% | 16.8% | 14.6% | 10.6% |
| ROIC | 8.5% | 8.5% | 6.3% | 3.7% | 1.1% | 1.3% | 2.8% | 7.3% | 44.4% | 30.4% | 25.6% |
| ROCE | 9.8% | 9.8% | 7.3% | 4.3% | 1.3% | 1.5% | 3.3% | 7.5% | 18.7% | 17.8% | 17.5% |
Solvency and debt-coverage ratios — lower is generally safer
HealthEquity, Inc. carries a Debt/EBITDA ratio of 3.1x, which is moderately leveraged (roughly in line with the sector average of 3.2x). Net debt stands at $683M ($1.0B total debt minus $319M cash). Interest coverage of 5.6x is adequate, though a cyclical earnings downturn could tighten the margin of safety.
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.48 | 0.48 | 0.52 | 0.46 | 0.52 | 0.54 | 0.78 | 1.26 | — | — | — |
| Debt / EBITDA | 3.11 | 3.11 | 2.82 | 3.32 | 5.00 | 5.67 | 5.49 | 7.91 | — | — | — |
| Net Debt / Equity | — | 0.32 | 0.38 | 0.26 | 0.39 | 0.42 | 0.54 | 1.08 | -0.76 | -0.58 | -0.53 |
| Net Debt / EBITDA | 2.12 | 2.12 | 2.07 | 1.88 | 3.72 | 4.40 | 3.81 | 6.75 | -3.77 | -2.83 | -2.57 |
| Debt / FCF | — | 1.50 | 2.41 | 2.69 | 23.48 | 200.00 | 8.81 | 17.39 | -3.67 | -4.13 | -4.25 |
| Interest Coverage | 5.64 | 5.64 | 2.89 | 2.33 | 0.21 | -0.94 | 1.12 | 2.74 | — | 191.47 | — |
Short-term solvency ratios and asset-utilisation metrics
HealthEquity, Inc.'s current ratio of 3.27x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 4.76x to 3.27x over the past 3 years.
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.27 | 3.27 | 3.06 | 4.76 | 2.92 | 2.29 | 2.25 | 1.96 | 13.58 | 12.95 | 12.79 |
| Quick Ratio | 3.27 | 3.27 | 3.06 | 4.76 | 2.92 | 2.29 | 2.25 | 1.96 | 13.58 | 12.94 | 12.75 |
| Cash Ratio | 2.03 | 2.03 | 1.89 | 3.45 | 1.94 | 1.47 | 1.61 | 1.26 | 12.44 | 11.73 | 11.49 |
| Asset Turnover | — | 0.38 | 0.35 | 0.32 | 0.28 | 0.24 | 0.27 | 0.21 | 0.56 | 0.62 | 0.64 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | 462.66 | 128.91 |
| Days Sales Outstanding | — | 34.37 | 35.90 | 38.30 | 41.02 | 42.18 | 36.21 | 48.62 | 32.62 | 34.35 | 34.79 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
HealthEquity, Inc. returns 4.2% to shareholders annually primarily through share buybacks. The earnings yield of 2.9% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 2.9% | 2.9% | 1.0% | 0.8% | — | — | 0.1% | 0.9% | 1.9% | 1.5% | 1.0% |
| FCF Yield | 6.4% | 6.1% | 3.4% | 3.0% | 0.6% | 0.1% | 1.3% | 1.4% | 2.5% | 1.5% | 1.2% |
| Buyback Yield | 4.2% | 4.0% | 1.2% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 4.2% | 4.0% | 1.2% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $87M | $89M | $87M | $84M | $83M | $76M | $68M | $63M | $62M | $60M |
Compare HQY with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| $7B | 34.6 | 24.2 | 15.7 | 69.5% | 24.6% | 10.2% | 8.5% | 3.1 | |
| $4B | 15.1 | 8.3 | 14.1 | 54.9% | 25.4% | 22.3% | 9.6% | 4.8 | |
| $17B | 36.3 | 23.7 | 18.8 | 80.3% | 6.9% | 3.7% | 1.6% | 11.7 | |
| $2B | 6.8 | 6.8 | 8.5 | 72.3% | 38.5% | 29.1% | 14.2% | 1.3 | |
| $9B | 133.2 | 138.8 | 30.4 | 62.5% | 3.4% | 5.0% | 2.3% | 11.0 | |
| $5B | 25.1 | 13.0 | 15.8 | 68.8% | 19.1% | 20.0% | 26.2% | 0.5 | |
| $7B | 15.5 | 8.9 | 16.7 | 78.6% | 27.6% | 27.4% | 30.7% | 0.2 | |
| $88B | 21.9 | 15.9 | 18.4 | 50.8% | 26.3% | 76.0% | 47.1% | 1.5 | |
| $35B | 21.4 | 16.0 | 20.0 | 72.4% | 39.6% | 41.8% | 30.9% | 2.1 | |
| $364B | 30.3 | 17.9 | 22.6 | 18.5% | 4.2% | 11.8% | 9.2% | 3.4 | |
| $125B | 70.7 | 14.0 | 16.1 | 13.8% | 2.6% | 2.3% | 5.0% | 6.2 | |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Includes 30+ ratios · 14 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying HQY stock.
HealthEquity, Inc.'s current P/E ratio is 34.6x. The historical average is 85.3x.
HealthEquity, Inc.'s current EV/EBITDA is 24.2x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 35.1x.
HealthEquity, Inc.'s return on equity (ROE) is 10.2%. The historical average is 8.6%.
Based on historical data, HealthEquity, Inc. is trading at a P/E of 34.6x. Compare with industry peers and growth rates for a complete picture.
HealthEquity, Inc. has 69.5% gross margin and 24.6% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
HealthEquity, Inc.'s Debt/EBITDA ratio is 3.1x, indicating high leverage. A ratio between 2-4x is manageable but warrants monitoring.